Be open about drug failures to speed up research
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
For drugs entering phase III, the probability of launch was 46% for cardiovascular indications versus 59% for anticancer indications.
“and for drugs entering phase III, values were 46% for cardiovascular versus 59% for anticancer. 8”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [8]
For drugs entering phase II RCTs, the probability of launch was 10% for cardiovascular indications and 23% for anticancer indications.
“For drugs entering phase II RCTs the comparable probabilities of launch were 10% for those with cardiovascular indications and 23% for anticancer indications”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [8]
Cites
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · see citing works
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 847 · see citing works
Jekel, K., Damian, M., Wattmo, C., Hausner, L., Bullock, R., Connelly, P. J., Dubois, B., Eriksdotter, M., Ewers, M., Graessel, E., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0099-0 · Cited by 640 · see citing works
Trials and Tribulations of CETP Inhibitors
Tall, A. R., & Rader, D. J. (2017) · Circulation Research · doi:10.1161/circresaha.117.311978 · Cited by 303 · see citing works
Taichman, D. B., Sahni, P., Pinborg, A. B., Peiperl, L., Laine, C. M., James, A., Hong, S., Haileamlak, A., Gollogly, L., Godlee, F., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1028 · Cited by 98 · see citing works
Transparency and the European Medicines Agency — Sharing of Clinical Trial Data
Bonini, S., Eichler, H., Wathion, N., & Rasi, G. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1409464 · Cited by 82 · see citing works
How Well Do the ADAS-cog and its Subscales Measure Cognitive Dysfunction in Alzheimer’s Disease?
Benge, J., Balsis, S., Geraci, L., Massman, P., & Doody, R. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000230709 · Cited by 77 · see citing works
Molzon, J. A., Giaquinto, A. R., Lindstrom, L., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.10 · Cited by 59 · see citing works
Guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease
Barcikowska, M. (2018) · Lekarz POZ · Cited by 30 · see citing works
Tocilizumab increased sustained glucocorticoid-free remission from giant cell arteritis
Milman, N. (2017) · Annals of Internal Medicine · doi:10.7326/acpjc-2017-167-12-063 · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Challenges and hopes for Alzheimer’s disease
Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291 · see citing works
Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184 · see citing works
Fang, J., Zhang, P., Wang, Q., Chiang, C.-W., Zhou, Y., Hou, Y., Xu, J., Chen, R., Zhang, B., Lewis, S. J., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00951-z · Cited by 140 · see citing works
Xu, J., Mao, C., Hou, Y., Luo, Y., Binder, J. L., Zhou, Y., Bekris, L. M., Shin, J., Hu, M., Wang, F., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111717 · Cited by 115 · see citing works
- Authors
- Alteri, E., & Guizzaro, L.
- Affiliations
- European Medicines Agency (NL)
- Corresponding author
- Alteri, Enrica
- ORCID
- Guizzaro, Lorenzo
- Venue
- Nature
- Published
- 2018-11-13
- Volume
- 563
- Issue
- 7731
- Pages
- 317-319
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2900608357
- Cited by
- 50
- References
- 10
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 4 · 2023: 9 · 2022: 7 · 2021: 10 · 2020: 6 · 2019: 7 · 2018: 1
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmaceutical industry and healthcare
- Social Sciences › Decision Sciences › Information Systems and Management › Academic Publishing and Open Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- drug failure, transparency, access to evidence, drug development, research acceleration, clinical trial data sharing
- MeSH terms
- Drug Development, Alzheimer Disease, Clinical Trials as Topic, Drug Industry, Humans, Time Factors, Truth Disclosure, Treatment Failure, Information Dissemination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
